LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).

被引：0
|
作者：
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Rambam Hlth Care Campus, Haifa, Israel
[3] Huntsman Canc Inst, Salt Lake City, UT USA
[4] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Merck & Co Inc, Rahway, NJ USA
[6] Westmead Hosp, Sydney, NSW, Australia
[7] Macquarie Univ, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4603
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The randomized phase 1/2 LITESPARK-024 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma (RCC)
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    CANCER RESEARCH, 2023, 83 (08)
  • [2] LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    ONCOLOGIST, 2023, 28 : S11 - S11
  • [4] Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003
    Choueiri, T. K.
    Bauer, T.
    Merchan, J.
    Figlin, R.
    Roy, A.
    Perini, R.
    Vickery, D.
    Arrowsmith, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [5] Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
    Agarwal, N.
    Brugarolas, J.
    Ghatalia, P.
    George, S.
    Haanen, J. B.
    Gurney, H.
    Ravilla, R.
    van der Veldt, A.
    Beuselinck, B.
    Pokataev, I.
    Suelmann, B. B. M.
    Tuthill, M. H.
    Vaena, D.
    Zagouri, F.
    Wu, J.
    Perini, R. F.
    Liu, Y.
    Merchan, J.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2024, 35 (12) : 1148 - 1156
  • [6] Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003
    McDermott, D. F.
    Choueiri, T. K.
    Tykodi, S.
    Merchan, J.
    Roy, A.
    Perini, R.
    Vickery, D.
    Bauer, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1208 - +
  • [7] LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Voss, Martin H.
    Plimack, Elizabeth R.
    Gurney, Howard
    Song, Yue
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian, I
    FUTURE ONCOLOGY, 2023, 19 (40) : 2631 - 2640
  • [8] Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
    Choueiri, T. K.
    Bauer, T.
    Merchan, J. R.
    McDermott, D. F.
    Figlin, R.
    Arrowsmith, E.
    Michaelson, M. D.
    Heath, E.
    D'Souza, A. A.
    Zhao, S.
    Mhamdi, L.
    Perini, R.
    Vickery, D.
    Tykodi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1328 - S1329
  • [9] Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
    Vaishampayan, U. N.
    Saavedra, A. J. Zurita
    Beckermann, K.
    Chain, A.
    Vickery, D.
    Zhang, Y.
    Perini, R.
    McDermott, D. F.
    ANNALS OF ONCOLOGY, 2024, 35 : S1016 - S1016
  • [10] Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study
    Agarwal, N.
    Brugarolas, J.
    Ghatalia, P.
    George, S.
    Haanen, J. B. A. G.
    Gurney, H. P.
    Ravilla, R.
    Van der Veldt, A. A. M.
    Beuselinck, B.
    Pokataev, I.
    Suelmann, B. B.
    Tuthill, M.
    Vaena, D.
    Zagouri, F.
    Wu, J.
    Liu, Y.
    Perini, R.
    Merchan, J. R.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1011 - S1011
12345